Скачать или смотреть Eli Lilly Is Not Great, Here Is Why

1) Stock Analysis Tools: https://stockanalysis.com/pro/?ref=st...
Discount Code: STOCKSNACK

The business history of Eli Lilly - My wife is convinced Eli Lilly stock is a bargain right now. I don't buy the hype. We project LLY's profit for the next 10 years to find out: Can this pharmaceutical titan beat the market, or is its high valuation hiding a serious investment failure?

In this essential "Stock Snack," we exclusively break down the price projection using three methods to find the simple truth:
1) The Valuation Fail: Our average 10-year projection shows a total return of 2.0X (or a $$$1,000 gain on a $$$1,000 investment). This is a massive failure compared to the S&P 500's projected 2.5X return!

2) The $67 Billion Paradox: We analyze a massive projected $67 Billion EBITDA by 2034, based on the company's strong 20.7% growth rate. We question why this massive expected profit still results in a market-losing return.

3) The Three-Method Loss: We reveal the results of all three valuation approaches (EBITDA, Free Cash Flow, and Dividend Gain). All three methods individually suggest that buying the S&P 500 is a better investment choice than buying LLY stock at its current price.

4) The Conclusion: The numbers show that Eli Lilly's current price is already discounting its explosive future growth, leaving little room for profit compared to a simple index fund.

Find out why the cold, hard numbers indicate that LLY is a great company, but a poor investment choice at its current valuation.


Long-Tail & Conceptual: Eli Lilly stock forecast 2034, LLY stock valuation, is LLY stock a buy, LLY vs S&P 500 return comparison, stock price projection method, EBITDA valuation explained, Free Cash Flow valuation.

#EliLilly #LLY #StockAnalysis #Investing #Valuation #PriceProjection #S&P500 #EBITDA #FinancialHealth #Stocksnack